Compare SRTAW & OSRHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SRTAW | OSRHW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 322 | 21 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2019 | 2023 |
| Metric | SRTAW | OSRHW |
|---|---|---|
| Price | $0.04 | $0.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.4K | 20.7K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.03 |
| 52 Week High | $0.29 | $0.08 |
| Indicator | SRTAW | OSRHW |
|---|---|---|
| Relative Strength Index (RSI) | 31.26 | 47.89 |
| Support Level | N/A | $0.04 |
| Resistance Level | $0.19 | $0.07 |
| Average True Range (ATR) | 0.01 | 0.00 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 17.17 | 15.67 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. Its core services include air and ground logistics, surgical organ recovery, organ placement, and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.